Detalhe da pesquisa
1.
Orismilast in moderate-to-severe psoriasis: Efficacy and safety from a 16-week, randomized, double-blinded, placebo-controlled, dose-finding, and phase 2b trial (IASOS).
J Am Acad Dermatol
; 90(3): 494-503, 2024 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-37951245